Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ra Pharmaceuticals
- ID
- NCT04115293
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated